We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Halozyme Therapeutics Incorporated | NASDAQ:HALO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.28 | 0.70% | 40.10 | 40.10 | 40.12 | 40.74 | 39.91 | 40.67 | 146,520 | 16:29:43 |
Date of Report (Date of Earliest Event Reported): | August 10, 2015 |
Delaware | 001-32335 | 88-0488686 | |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
11388 Sorrento Valley Road, San Diego, California | 92121 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: | (858) 794-8889 |
Exhibit No. | Description |
99.1 | Press release dated August 10, 2015 |
HALOZYME THERAPEUTICS, INC. | ||||
August 10, 2015 | By: | /s/ Harry J. Leonhardt,, Esq. | ||
Name: | Harry J. Leonhardt,, Esq. | |||
Title: | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
Exhibit No. | Description | |
99.1 | Press release dated August 10, 2015 |
• | Global clinical collaboration with Eisai Co., Ltd. to investigate HALAVEN® (eribulin) and PEGPH20 in metastatic breast cancer: Halozyme entered into a worldwide clinical collaboration with Eisai Co. Ltd. to evaluate HALAVEN in combination with PEGPH20 in first line HER2-negative metastatic breast cancer patients. The companies will co-fund a phase 1b/2 clinical trial to explore whether HALAVEN in combination with PEGPH20 can improve overall response rate, as compared with HALAVEN alone. |
• | Received feedback from the European Medicines Agency (EMA) on the Phase 3 Study 301 design. During the quarter, the company received scientific advice from the EMA for its planned Phase 3 registration study in metastatic pancreatic cancer patients with high-HA tumors. Based on feedback received to date from the U.S. Food and Drug Administration (FDA) and the EMA, the company plans to proceed with the |
• | Global collaboration with AbbVie to develop and commercialize products using ENHANZE™ technology: Halozyme entered into a worldwide collaboration and license agreement with AbbVie for the purpose of developing and commercializing products combining proprietary AbbVie compounds with Halozyme's ENHANZE technology. Halozyme received an initial payment of $23 million in June 2015. The agreement provides for milestone payments totaling approximately $130 million for each of up to nine collaboration targets, in addition to tiered royalty payments based on net sales of products using ENHANZE technology. |
• | Interim results from Study 202 evaluating PEGPH20 with gemcitabine and ABRAXANE® (nab-paclitaxel) in metastatic pancreatic cancer patients were presented at the annual meeting of the American Society of Clinical Oncology (ASCO): In a retrospectively defined sub-population of patients, the data showed a doubling in median progression free survival in metastatic pancreatic cancer patients with high levels of hyaluronan (HA) who were treated with PEGPH20 combined with ABRAXANE and gemcitabine (9.2 months vs. 4.3 months in patients treated with ABRAXANE and gemcitabine alone). Additional reported results included: |
◦ | A more than doubling of overall response rate of 52 percent versus 24 percent (p-value of 0.038) and a duration of response of 8.1 months compared to 3.7 months in high HA patients treated with PEGPH20 combined with ABRAXANE and gemcitabine (PAG) versus ABRAXANE and gemcitabine (AG); |
◦ | A trend toward improvement in median overall survival of 12 months compared to 9 months in high HA patients treated with PAG versus AG (hazard ratio of 0.62) despite discontinuation of PEGPH20 in more than half of the PAG-treated patients at the time of the clinical hold in April 2014; |
◦ | A thromboembolic event (TE) event rate of 13 percent in 38 patients treated with PAG versus 18 percent in 17 patients receiving AG. |
• | Global agreement with Ventana Medical Systems to collaboratively develop a companion diagnostic for cancer treatment: Entered into a global agreement with Ventana to develop and commercialize a companion diagnostic assay for use with PEGPH20. Under the agreement, Ventana will develop the in vitro diagnostic, with the intent of submitting it for regulatory approval in the United States, Europe and other countries. |
• | Revenues for the second quarter of 2015 were $43.4 million, compared to $18.4 million for the second quarter of 2014, driven by a $23 million payment for initiation of a global collaboration agreement with AbbVie. Revenues in the second quarter included $6.4 million in royalty revenue from sales of products under collaboration agreements, $7.7 million in product sales of bulk rHuPH20 for use in manufacturing collaboration products for Roche and Baxalta, $4.2 million in Hylenex® recombinant (hyaluronidase human injection) product sales, and $24.7 million in collaboration revenues, which includes the $23 million payment from AbbVie. Royalty revenues represent January to March 2015 partnered product sales as a result of the one quarter lag in royalty reports. |
• | Research and development expenses for the second quarter of 2015 were $21.2 million, compared to $18.6 million for the second quarter of 2014. The increase was primarily due to an increase in expenses related to preclinical and clinical activities for PEGPH20, off-set by a planned decrease in expenses associated with discontinued development programs. |
• | Selling, general and administrative expenses for the second quarter of 2015 were $9.8 million, compared to $8.8 million for the second quarter of 2014. The increase was primarily due to an increase in personnel expenses, including stock compensation, for the period. |
• | Net income for the second quarter of 2015 was $3.0 million, or $0.02 per share, compared to a net loss for the second quarter of 2014 of $16.3 million, or $0.13 per share. |
• | Cash, cash equivalents and marketable securities were $140.7 million at June 30, 2015, compared to $128.5 million at March 31, 2015. Net cash increase in the second quarter of 2015 was approximately $12.2 million. |
• | Net revenues to be in the range of $110 million to $115 million, from a prior range of $85 million to $95 million. |
• | Operating expenses to be in the range of $160 million to $170 million, from a prior range of $145 million to $155 million. |
• | Net cash burn to be between $20 million to $30 million, from a prior range of $35 to $45 million, with year-end cash balance expected to be $105 million to $115 million. |
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2015 | 2014 | 2015 | 2014 | |||||||||||||
Revenues: | ||||||||||||||||
Product sales, net | $ | 12,342 | $ | 9,494 | $ | 22,202 | $ | 18,062 | ||||||||
Royalties | 6,382 | 1,688 | 13,157 | 2,487 | ||||||||||||
Revenues under collaborative agreements | 24,660 | 7,203 | 26,691 | 9,802 | ||||||||||||
Total revenues | 43,384 | 18,385 | 62,050 | 30,351 | ||||||||||||
Operating expenses: | ||||||||||||||||
Cost of product sales | 8,144 | 5,924 | 14,638 | 11,444 | ||||||||||||
Research and development | 21,195 | 18,649 | 37,879 | 40,064 | ||||||||||||
Selling, general and administrative | 9,814 | 8,752 | 19,213 | 19,002 | ||||||||||||
Total operating expenses | 39,153 | 33,325 | 71,730 | 70,510 | ||||||||||||
Operating income (loss) | 4,231 | (14,940 | ) | (9,680 | ) | (40,159 | ) | |||||||||
Other income (expense): | ||||||||||||||||
Investment and other income, net | 87 | 118 | 189 | 165 | ||||||||||||
Interest expense | (1,299 | ) | (1,451 | ) | (2,598 | ) | (2,827 | ) | ||||||||
Net income (loss) | $ | 3,019 | $ | (16,273 | ) | $ | (12,089 | ) | $ | (42,821 | ) | |||||
Net income (loss) per share: | ||||||||||||||||
Basic | $ | 0.02 | $ | (0.13 | ) | $ | (0.10 | ) | $ | (0.35 | ) | |||||
Diluted | $ | 0.02 | $ | (0.13 | ) | $ | (0.10 | ) | $ | (0.35 | ) | |||||
Shares used in computing net income (loss) per share: | ||||||||||||||||
Basic | 126,144 | 123,710 | 125,723 | 121,200 | ||||||||||||
Diluted | 134,507 | 123,710 | 125,723 | 121,200 |
June 30, 2015 | December 31, 2014 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 67,769 | $ | 61,389 | ||||
Marketable securities, available-for-sale | 72,946 | 74,234 | ||||||
Accounts receivable, net | 9,738 | 9,149 | ||||||
Inventories | 7,723 | 6,406 | ||||||
Prepaid expenses and other assets | 10,266 | 10,143 | ||||||
Total current assets | 168,442 | 161,321 | ||||||
Property and equipment, net | 2,594 | 2,951 | ||||||
Prepaid expenses and other assets | 2,511 | 1,205 | ||||||
Restricted cash | 500 | 500 | ||||||
Total assets | $ | 174,047 | $ | 165,977 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 4,138 | $ | 3,003 | ||||
Accrued expenses | 14,821 | 13,961 | ||||||
Deferred revenue, current portion | 6,424 | 7,367 | ||||||
Current portion of long-term debt, net | 9,656 | — | ||||||
Total current liabilities | 35,039 | 24,331 | ||||||
Deferred revenue, net of current portion | 45,252 | 47,267 | ||||||
Long-term debt, net | 40,098 | 49,860 | ||||||
Other long-term liabilities | 3,429 | 3,167 | ||||||
Stockholders’ equity: | ||||||||
Common stock | 128 | 126 | ||||||
Additional paid-in capital | 512,657 | 491,694 | ||||||
Accumulated other comprehensive loss | (40 | ) | (41 | ) | ||||
Accumulated deficit | (462,516 | ) | (450,427 | ) | ||||
Total stockholders’ equity | 50,229 | 41,352 | ||||||
Total liabilities and stockholders’ equity | $ | 174,047 | $ | 165,977 |
1 Year Halozyme Therapeutics Chart |
1 Month Halozyme Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions